Search

Your search keyword '"Tramm, Trine"' showing total 276 results
Start Over Author "Tramm, Trine"
276 results on '"Tramm, Trine"'

5. Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma – A DAHANCA 19 study

Author

Kristensen, Morten Horsholt, Sørensen, Mia Kristina, Tramm, Trine, Alsner, Jan, Sørensen, Brita Singers, Maare, Christian, Johansen, Jørgen, Primdahl, Hanne, Bratland, Åse, Kristensen, Claus Andrup, Andersen, Maria, Lilja-Fischer, Jacob Kinggaard, Holm, Anne Ivalu Sander, Samsøe, Eva, Hansen, Christian Rønn, Zukauskaite, Ruta, Overgaard, Jens, and Eriksen, Jesper Grau

Published
2024
Full Text
View/download PDF

8. The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus

Author

Kaidar-Person, Orit, Pfob, André, Gentilini, Oreste Davide, Borisch, Bettina, Bosch, Ana, Cardoso, Maria João, Curigliano, Giuseppe, De Boniface, Jana, Denkert, Carsten, Hauser, Nik, Heil, Jörg, Knauer, Michael, Kühn, Thorsten, Lee, Han-Byoel, Loibl, Sibylle, Mannhart, Meinrad, Meattini, Icro, Montagna, Giacomo, Pinker, Katja, Poulakaki, Fiorita, Rubio, Isabel T., Sager, Patrizia, Steyerova, Petra, Tausch, Christoph, Tramm, Trine, Vrancken Peeters, Marie-Jeanne, Wyld, Lynda, Yu, Jong Han, Weber, Walter Paul, Poortmans, Philip, and Dubsky, Peter

Published
2023
Full Text
View/download PDF

9. Pathology Report

Author

Tramm, Trine, Moinfar, Farid, Kaidar-Person, Orit, editor, Meattini, Icro, editor, and Poortmans, Philip, editor

Published
2022
Full Text
View/download PDF

14. A Novel and Reliable Pixel Response Correction Method (DAC-Shifting) for Spectral Photon-Counting CT Imaging.

Author

Bal, Navrit Johan Singh, Chitra Ragupathy, Imaiyan, Tramm, Trine, and Nijkamp, Jasper

Subjects
DUAL energy CT (Tomography), CONE beam computed tomography, SPECTRAL sensitivity, COMPUTED tomography, SPECTRAL imaging
Abstract

Spectral photon-counting cone-beam computed tomography (CT) imaging is challenged by individual pixel response behaviours, which lead to noisy projection images and subsequent image artefacts like rings. Existing methods to correct for this either use calibration measurements, like signal-to-thickness calibration (STC), or perform a post-processing ring artefact correction of sinogram data or scan reconstructions without taking the pixel response explicitly into account. Here, we present a novel post-processing method (digital-to-analogue converter (DAC)-shifting) which explicitly measures the current pixel response using flat-field images and subsequently corrects the projection data. The DAC-shifting method was evaluated using a repeat series of the spectral photon-counting imaging (Medipix3) of a phantom with different density inserts and iodine K-edge imaging. The method was also compared against polymethyl methacrylate (PMMA)-based STC. The DAC-shifting method was shown to be effective in correcting individual pixel responses and was robust against detector instability; it led to a 47.4% average reduction in CT-number variation in homogeneous materials, with a range of 40.7–55.6%. On the contrary, the STC correction showed varying results; a 13.7% average reduction in CT-number variation, ranging from a 43.7% increase to a 45.5% reduction. In K-edge imaging, DAC-shifting provides a sharper attenuation peak and more uniform CT values, which are expected to benefit iodine concentration quantifications. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer

Author

Jahangir, Chowdhury Arif, primary, Page, David B, additional, Broeckx, Glenn, additional, Gonzalez, Claudia A, additional, Burke, Caoimbhe, additional, Murphy, Clodagh, additional, Reis‐Filho, Jorge S, additional, Ly, Amy, additional, Harms, Paul W, additional, Gupta, Rajarsi R, additional, Vieth, Michael, additional, Hida, Akira I, additional, Kahila, Mohamed, additional, Kos, Zuzana, additional, van Diest, Paul J, additional, Verbandt, Sara, additional, Thagaard, Jeppe, additional, Khiroya, Reena, additional, Abduljabbar, Khalid, additional, Acosta Haab, Gabriela, additional, Acs, Balazs, additional, Adams, Sylvia, additional, Almeida, Jonas S, additional, Alvarado‐Cabrero, Isabel, additional, Azmoudeh‐Ardalan, Farid, additional, Badve, Sunil, additional, Baharun, Nurkhairul Bariyah, additional, Bellolio, Enrique R, additional, Bheemaraju, Vydehi, additional, Blenman, Kim RM, additional, Botinelly Mendonça Fujimoto, Luciana, additional, Burgues, Octavio, additional, Chardas, Alexandros, additional, Cheang, Maggie Chon U, additional, Ciompi, Francesco, additional, Cooper, Lee AD, additional, Coosemans, An, additional, Corredor, Germán, additional, Dantas Portela, Flavio Luis, additional, Deman, Frederik, additional, Demaria, Sandra, additional, Dudgeon, Sarah N, additional, Elghazawy, Mahmoud, additional, Fernandez‐Martín, Claudio, additional, Fineberg, Susan, additional, Fox, Stephen B, additional, Giltnane, Jennifer M, additional, Gnjatic, Sacha, additional, Gonzalez‐Ericsson, Paula I, additional, Grigoriadis, Anita, additional, Halama, Niels, additional, Hanna, Matthew G, additional, Harbhajanka, Aparna, additional, Hart, Steven N, additional, Hartman, Johan, additional, Hewitt, Stephen, additional, Horlings, Hugo M, additional, Husain, Zaheed, additional, Irshad, Sheeba, additional, Janssen, Emiel AM, additional, Kataoka, Tatsuki R, additional, Kawaguchi, Kosuke, additional, Khramtsov, Andrey I, additional, Kiraz, Umay, additional, Kirtani, Pawan, additional, Kodach, Liudmila L, additional, Korski, Konstanty, additional, Akturk, Guray, additional, Scott, Ely, additional, Kovács, Anikó, additional, Lænkholm, Anne‐Vibeke, additional, Lang‐Schwarz, Corinna, additional, Larsimont, Denis, additional, Lennerz, Jochen K, additional, Lerousseau, Marvin, additional, Li, Xiaoxian, additional, Madabhushi, Anant, additional, Maley, Sai K, additional, Manur Narasimhamurthy, Vidya, additional, Marks, Douglas K, additional, McDonald, Elizabeth S, additional, Mehrotra, Ravi, additional, Michiels, Stefan, additional, Kharidehal, Durga, additional, Minhas, Fayyaz ul Amir Afsar, additional, Mittal, Shachi, additional, Moore, David A, additional, Mushtaq, Shamim, additional, Nighat, Hussain, additional, Papathomas, Thomas, additional, Penault‐Llorca, Frederique, additional, Perera, Rashindrie D, additional, Pinard, Christopher J, additional, Pinto‐Cardenas, Juan Carlos, additional, Pruneri, Giancarlo, additional, Pusztai, Lajos, additional, Rajpoot, Nasir Mahmood, additional, Rapoport, Bernardo Leon, additional, Rau, Tilman T, additional, Ribeiro, Joana M, additional, Rimm, David, additional, Vincent‐Salomon, Anne, additional, Saltz, Joel, additional, Sayed, Shahin, additional, Hytopoulos, Evangelos, additional, Mahon, Sarah, additional, Siziopikou, Kalliopi P, additional, Sotiriou, Christos, additional, Stenzinger, Albrecht, additional, Sughayer, Maher A, additional, Sur, Daniel, additional, Symmans, Fraser, additional, Tanaka, Sunao, additional, Taxter, Timothy, additional, Tejpar, Sabine, additional, Teuwen, Jonas, additional, Thompson, E Aubrey, additional, Tramm, Trine, additional, Tran, William T, additional, van der Laak, Jeroen, additional, Verghese, Gregory E, additional, Viale, Giuseppe, additional, Wahab, Noorul, additional, Walter, Thomas, additional, Waumans, Yannick, additional, Wen, Hannah Y, additional, Yang, Wentao, additional, Yuan, Yinyin, additional, Bartlett, John, additional, Loibl, Sibylle, additional, Denkert, Carsten, additional, Savas, Peter, additional, Loi, Sherene, additional, Specht Stovgaard, Elisabeth, additional, Salgado, Roberto, additional, Gallagher, William M, additional, and Rahman, Arman, additional

Published
2024
Full Text
View/download PDF

18. Antibodies toward Na+,HCO3–-cotransporter NBCn1/SLC4A7 block net acid extrusion and cause pH-dependent growth inhibition and apoptosis in breast cancer.

Author

Axelsen, Trine V., Olesen, Claus, Khan, Danish, Mohammadi, Ali, Bouzinova, Elena V., Nielsen, Christine J. F., Mele, Marco, Hauerslev, Katrine R., Pedersen, Helene L., Balling, Eva, Vahl, Pernille, Tramm, Trine, Christiansen, Peer M., and Boedtkjer, Ebbe

Abstract

Background: Na+,HCO3–-cotransporter NBCn1/Slc4a7 accelerates murine breast carcinogenesis. Lack of specific pharmacological tools previously restricted therapeutic targeting of NBCn1 and identification of NBCn1-dependent functions in human breast cancer. Methods: We develop extracellularly-targeted anti-NBCn1 antibodies, screen for functional activity on cells, and evaluate (a) mechanisms of intracellular pH regulation in human primary breast carcinomas, (b) proliferation, cell death, and tumor growth consequences of NBCn1 in triple-negative breast cancer, and (c) association of NBCn1-mediated Na+,HCO3–-cotransport with human breast cancer metastasis. Results: We identify high-affinity (KD ≈ 0.14 nM) anti-NBCn1 antibodies that block human NBCn1-mediated Na+,HCO3–-cotransport in cells, without cross-reactivity towards human NBCe1 or murine NBCn1. These anti-NBCn1 antibodies abolish Na+,HCO3–-cotransport activity in freshly isolated primary organoids from human breast carcinomas and lower net acid extrusion effectively in primary breast cancer tissue from patients with macrometastases in axillary lymph nodes. Inhibitory anti-NBCn1 antibodies decelerate tumor growth in vivo by ~50% in a patient-derived xenograft model of triple-negative breast cancer and pH-dependently reduce colony formation, cause G2/M-phase cell cycle accumulation, and increase apoptosis of metastatic triple-negative breast cancer cells in vitro. Conclusions: Inhibitory anti-NBCn1 antibodies block net acid extrusion in human breast cancer tissue, particularly from patients with disseminated disease, and pH-dependently limit triple-negative breast cancer growth. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. The 5p12 breast cancer susceptibility locus affects MRPS30 expression in estrogen‐receptor positive tumors

Author

Quigley, David A, Fiorito, Elisa, Nord, Silje, Van Loo, Peter, Alnæs, Grethe Grenaker, Fleischer, Thomas, Tost, Jorg, Vollan, Hans Kristian Moen, Tramm, Trine, Overgaard, Jens, Bukholm, Ida R, Hurtado, Antoni, Balmain, Allan, Børresen-Dale, Anne-Lise, and Kristensen, Vessela

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Aging, Breast Cancer, Human Genome, Estrogen, Cancer, Genetics, Prevention, 2.1 Biological and endogenous factors, Aetiology, Alleles, Cell Line, Tumor, Female, Gene Expression Regulation, Neoplastic, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Neoplasm Proteins, Quantitative Trait Loci, Receptors, Estrogen, Breast cancer, Expression Quantitative Trait Locus, chromatin, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Genome-wide association studies have identified numerous loci linked to breast cancer susceptibility, but the mechanism by which variations at these loci influence susceptibility is usually unknown. Some variants are only associated with particular clinical subtypes of breast cancer. Understanding how and why these variants influence subtype-specific cancer risk contributes to our understanding of cancer etiology. We conducted a genome-wide expression Quantitative Trait Locus (eQTL) study in a discovery set of 287 breast tumors and 97 normal mammary tissue samples and a replication set of 235 breast tumors. We found that the risk-associated allele of rs7716600 in the 5p12 estrogen receptor-positive (ER-positive) susceptibility locus was associated with elevated expression of the nearby gene MRPS30 exclusively in ER-positive tumors. We replicated this finding in 235 independent tumors. Further, we showed the rs7716600 risk genotype was associated with decreased MRPS30 promoter methylation exclusively in ER-positive breast tumors. In vitro studies in MCF-7 cells carrying the protective genotype showed that estrogen stimulation decreased MRPS30 promoter chromatin availability and mRNA levels. In contrast, in 600MPE cells carrying the risk genotype, estrogen increased MRPS30 expression and did not affect promoter availability. Our data suggest the 5p12 risk allele affects MRPS30 expression in estrogen-responsive tumor cells after tumor initiation by a mechanism affecting chromatin availability. These studies emphasize that the genetic architecture of breast cancer is context-specific, and integrated analysis of gene expression and chromatin remodeling in normal and tumor tissues will be required to explain the mechanisms of risk alleles.

Published
2014

20. Increased lesion detectability in patients with locally advanced breast cancer—A pilot study using dynamic whole-body [18F]FDG PET/CT.

Author

Pedersen, Mette Abildgaard, Dias, André H., Hjorthaug, Karin, Gormsen, Lars C., Fledelius, Joan, Johnsson, Anna Lyhne, Borgquist, Signe, Tramm, Trine, Munk, Ole Lajord, and Vendelbo, Mikkel Holm

Subjects
CANCER patients, MAGNETIC resonance mammography, SENTINEL lymph node biopsy, METASTATIC breast cancer, POSITRON emission tomography, COMPUTED tomography
Abstract

Background: Accurate diagnosis of axillary lymph node (ALN) metastases is essential for prognosis and treatment planning in breast cancer. Evaluation of ALN is done by ultrasound, which is limited by inter-operator variability, and by sentinel lymph node biopsy and/or ALN dissection, none of which are without risks and/or long-term complications. It is known that conventional 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) has limited sensitivity for ALN metastases. However, a recently developed dynamic whole-body (D-WB) [18F]FDG PET/CT scanning protocol, allowing for imaging of tissue [18F]FDG metabolic rate (MRFDG), has been shown to have the potential to increase lesion detectability. The study purpose was to examine detectability of malignant lesions in D-WB [18F]FDG PET/CT compared to conventional [18F]FDG PET/CT. Results: This study prospectively included ten women with locally advanced breast cancer who were referred for an [18F]FDG PET/CT as part of their diagnostic work-up. They all underwent D-WB [18F]FDG PET/CT, consisting of a 6 min single bed dynamic scan over the chest region started at the time of tracer injection, a 64 min dynamic WB PET scan consisting of 16 continuous bed motion passes, and finally a contrast-enhanced CT scan, with generation of MRFDG parametric images. Lesion visibility was assessed by tumor-to-background and contrast-to-noise ratios using volumes of interest isocontouring tumors with a set limit of 50% of SUVmax and background volumes placed in the vicinity of tumors. Lesion visibility was best in the MRFDG images, with target-to-background values 2.28 (95% CI: 2.04–2.54) times higher than target-to-background values in SUV images, and contrast-to-noise values 1.23 (95% CI: 1.12–1.35) times higher than contrast-to-noise values in SUV images. Furthermore, five imaging experts visually assessed the images and three additional suspicious lesions were found in the MRFDG images compared to SUV images; one suspicious ALN, one suspicious parasternal lymph node, and one suspicious lesion located in the pelvic bone. Conclusions: D-WB [18F]FDG PET/CT with MRFDG images show potential for improved lesion detectability compared to conventional SUV images in locally advanced breast cancer. Further validation in larger cohorts is needed. Clinical trial registration: The trial is registered in clinicaltrials.gov, NCT05110443, https://www.clinicaltrials.gov/study/NCT05110443?term=NCT05110443&rank=1. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Dynamic whole-body [18F]FES PET/CT increases lesion visibility in patients with metastatic breast cancer.

Author

Pedersen, Mette A., Munk, Ole L., Dias, André H., Steffensen, Johanne H., Møller, Anders L., Johnsson, Anna Lyhne, Hansen, Kim Vang, Bender, Dirk, Jakobsen, Steen, Busk, Morten, Gormsen, Lars C., Tramm, Trine, Borgquist, Signe, and Vendelbo, Mikkel H.

Subjects
METASTATIC breast cancer, POSITRON emission tomography, MAGNETIC resonance mammography, COMPUTED tomography, ESTROGEN receptors
Abstract

Background: Correct classification of estrogen receptor (ER) status is essential for prognosis and treatment planning in patients with breast cancer (BC). Therefore, it is recommended to sample tumor tissue from an accessible metastasis. However, ER expression can show intra- and intertumoral heterogeneity. 16α-[18F]fluoroestradiol ([18F]FES) Positron Emission Tomography/Computed Tomography (PET/CT) allows noninvasive whole-body (WB) identification of ER distribution and is usually performed as a single static image 60 min after radiotracer injection. Using dynamic whole-body (D-WB) PET imaging, we examine [18F]FES kinetics and explore whether Patlak parametric images ( K i ) are quantitative and improve lesion visibility. Results: This prospective study included eight patients with metastatic ER-positive BC scanned using a D-WB PET acquisition protocol. The kinetics of [18F]FES were best characterized by the irreversible two-tissue compartment model in tumor lesions and in the majority of organ tissues. K i values from Patlak parametric images correlated with K i values from the full kinetic analysis, r2 = 0.77, and with the semiquantitative mean standardized uptake value (SUVmean), r2 = 0.91. Furthermore, parametric K i images had the highest target-to-background ratio (TBR) in 162/164 metastatic lesions and the highest contrast-to-noise ratio (CNR) in 99/164 lesions compared to conventional SUV images. TBR was 2.45 (95% confidence interval (CI): 2.25–2.68) and CNR 1.17 (95% CI: 1.08–1.26) times higher in K i images compared to SUV images. These quantitative differences were seen as reduced background activity in the K i images. Conclusion: [18F]FES uptake is best described by an irreversible two-tissue compartment model. D-WB [18F]FES PET/CT scans can be used for direct reconstruction of parametric K i images, with superior lesion visibility and K i values comparable to K i values found from full kinetic analyses. This may aid correct ER classification and treatment decisions. Trial registration ClinicalTrials.gov: NCT04150731, https://clinicaltrials.gov/study/NCT04150731 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Spatial analyses of immune cell infiltration in cancer: current methods and future directions. A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer

Author

Page, David B, primary, Broeckx, Glenn, additional, Jahangir, Chowdhury Arif, additional, Verbandt, Sara, additional, Gupta, Rajarsi R, additional, Thagaard, Jeppe, additional, Khiroya, Reena, additional, Kos, Zuzana, additional, Abduljabbar, Khalid, additional, Acosta Haab, Gabriela, additional, Acs, Balazs, additional, Almeida, Jonas S, additional, Alvarado‐Cabrero, Isabel, additional, Azmoudeh‐Ardalan, Farid, additional, Badve, Sunil, additional, Baharun, Nurkhairul Bariyah, additional, Bellolio, Enrique R, additional, Bheemaraju, Vydehi, additional, Blenman, Kim RM, additional, Botinelly Mendonça Fujimoto, Luciana, additional, Burgues, Octavio, additional, Cheang, Maggie Chon U, additional, Ciompi, Francesco, additional, Cooper, Lee AD, additional, Coosemans, An, additional, Corredor, Germán, additional, Dantas Portela, Flavio Luis, additional, Deman, Frederik, additional, Demaria, Sandra, additional, Dudgeon, Sarah N, additional, Elghazawy, Mahmoud, additional, Ely, Scott, additional, Fernandez‐Martín, Claudio, additional, Fineberg, Susan, additional, Fox, Stephen B, additional, Gallagher, William M, additional, Giltnane, Jennifer M, additional, Gnjatic, Sacha, additional, Gonzalez‐Ericsson, Paula I, additional, Grigoriadis, Anita, additional, Halama, Niels, additional, Hanna, Matthew G, additional, Harbhajanka, Aparna, additional, Hardas, Alexandros, additional, Hart, Steven N, additional, Hartman, Johan, additional, Hewitt, Stephen, additional, Hida, Akira I, additional, Horlings, Hugo M, additional, Husain, Zaheed, additional, Hytopoulos, Evangelos, additional, Irshad, Sheeba, additional, Janssen, Emiel AM, additional, Kahila, Mohamed, additional, Kataoka, Tatsuki R, additional, Kawaguchi, Kosuke, additional, Kharidehal, Durga, additional, Khramtsov, Andrey I, additional, Kiraz, Umay, additional, Kirtani, Pawan, additional, Kodach, Liudmila L, additional, Korski, Konstanty, additional, Kovács, Anikó, additional, Laenkholm, Anne‐Vibeke, additional, Lang‐Schwarz, Corinna, additional, Larsimont, Denis, additional, Lennerz, Jochen K, additional, Lerousseau, Marvin, additional, Li, Xiaoxian, additional, Ly, Amy, additional, Madabhushi, Anant, additional, Maley, Sai K, additional, Manur Narasimhamurthy, Vidya, additional, Marks, Douglas K, additional, McDonald, Elizabeth S, additional, Mehrotra, Ravi, additional, Michiels, Stefan, additional, Minhas, Fayyaz ul Amir Afsar, additional, Mittal, Shachi, additional, Moore, David A, additional, Mushtaq, Shamim, additional, Nighat, Hussain, additional, Papathomas, Thomas, additional, Penault‐Llorca, Frederique, additional, Perera, Rashindrie D, additional, Pinard, Christopher J, additional, Pinto‐Cardenas, Juan Carlos, additional, Pruneri, Giancarlo, additional, Pusztai, Lajos, additional, Rahman, Arman, additional, Rajpoot, Nasir Mahmood, additional, Rapoport, Bernardo Leon, additional, Rau, Tilman T, additional, Reis‐Filho, Jorge S, additional, Ribeiro, Joana M, additional, Rimm, David, additional, Salomon, Anne‐Vincent, additional, Salto‐Tellez, Manuel, additional, Saltz, Joel, additional, Sayed, Shahin, additional, Siziopikou, Kalliopi P, additional, Sotiriou, Christos, additional, Stenzinger, Albrecht, additional, Sughayer, Maher A, additional, Sur, Daniel, additional, Symmans, Fraser, additional, Tanaka, Sunao, additional, Taxter, Timothy, additional, Tejpar, Sabine, additional, Teuwen, Jonas, additional, Thompson, E Aubrey, additional, Tramm, Trine, additional, Tran, William T, additional, van der Laak, Jeroen, additional, van Diest, Paul J, additional, Verghese, Gregory E, additional, Viale, Giuseppe, additional, Vieth, Michael, additional, Wahab, Noorul, additional, Walter, Thomas, additional, Waumans, Yannick, additional, Wen, Hannah Y, additional, Yang, Wentao, additional, Yuan, Yinyin, additional, Adams, Sylvia, additional, Bartlett, John Mark Seaverns, additional, Loibl, Sibylle, additional, Denkert, Carsten, additional, Savas, Peter, additional, Loi, Sherene, additional, Salgado, Roberto, additional, Specht Stovgaard, Elisabeth, additional, Akturk, Guray, additional, and Bouchmaa, Najat, additional

Published
2023
Full Text
View/download PDF

24. Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: a report of the international immuno‐oncology biomarker working group

Author

Thagaard, Jeppe, primary, Broeckx, Glenn, additional, Page, David B, additional, Jahangir, Chowdhury Arif, additional, Verbandt, Sara, additional, Kos, Zuzana, additional, Gupta, Rajarsi, additional, Khiroya, Reena, additional, Abduljabbar, Khalid, additional, Acosta Haab, Gabriela, additional, Acs, Balazs, additional, Akturk, Guray, additional, Almeida, Jonas S, additional, Alvarado‐Cabrero, Isabel, additional, Amgad, Mohamed, additional, Azmoudeh‐Ardalan, Farid, additional, Badve, Sunil, additional, Baharun, Nurkhairul Bariyah, additional, Balslev, Eva, additional, Bellolio, Enrique R, additional, Bheemaraju, Vydehi, additional, Blenman, Kim RM, additional, Botinelly Mendonça Fujimoto, Luciana, additional, Bouchmaa, Najat, additional, Burgues, Octavio, additional, Chardas, Alexandros, additional, Chon U Cheang, Maggie, additional, Ciompi, Francesco, additional, Cooper, Lee AD, additional, Coosemans, An, additional, Corredor, Germán, additional, Dahl, Anders B, additional, Dantas Portela, Flavio Luis, additional, Deman, Frederik, additional, Demaria, Sandra, additional, Doré Hansen, Johan, additional, Dudgeon, Sarah N, additional, Ebstrup, Thomas, additional, Elghazawy, Mahmoud, additional, Fernandez‐Martín, Claudio, additional, Fox, Stephen B, additional, Gallagher, William M, additional, Giltnane, Jennifer M, additional, Gnjatic, Sacha, additional, Gonzalez‐Ericsson, Paula I, additional, Grigoriadis, Anita, additional, Halama, Niels, additional, Hanna, Matthew G, additional, Harbhajanka, Aparna, additional, Hart, Steven N, additional, Hartman, Johan, additional, Hauberg, Søren, additional, Hewitt, Stephen, additional, Hida, Akira I, additional, Horlings, Hugo M, additional, Husain, Zaheed, additional, Hytopoulos, Evangelos, additional, Irshad, Sheeba, additional, Janssen, Emiel AM, additional, Kahila, Mohamed, additional, Kataoka, Tatsuki R, additional, Kawaguchi, Kosuke, additional, Kharidehal, Durga, additional, Khramtsov, Andrey I, additional, Kiraz, Umay, additional, Kirtani, Pawan, additional, Kodach, Liudmila L, additional, Korski, Konstanty, additional, Kovács, Anikó, additional, Laenkholm, Anne‐Vibeke, additional, Lang‐Schwarz, Corinna, additional, Larsimont, Denis, additional, Lennerz, Jochen K, additional, Lerousseau, Marvin, additional, Li, Xiaoxian, additional, Ly, Amy, additional, Madabhushi, Anant, additional, Maley, Sai K, additional, Manur Narasimhamurthy, Vidya, additional, Marks, Douglas K, additional, McDonald, Elizabeth S, additional, Mehrotra, Ravi, additional, Michiels, Stefan, additional, Minhas, Fayyaz ul Amir Afsar, additional, Mittal, Shachi, additional, Moore, David A, additional, Mushtaq, Shamim, additional, Nighat, Hussain, additional, Papathomas, Thomas, additional, Penault‐Llorca, Frederique, additional, Perera, Rashindrie D, additional, Pinard, Christopher J, additional, Pinto‐Cardenas, Juan Carlos, additional, Pruneri, Giancarlo, additional, Pusztai, Lajos, additional, Rahman, Arman, additional, Rajpoot, Nasir Mahmood, additional, Rapoport, Bernardo Leon, additional, Rau, Tilman T, additional, Reis‐Filho, Jorge S, additional, Ribeiro, Joana M, additional, Rimm, David, additional, Roslind, Anne, additional, Vincent‐Salomon, Anne, additional, Salto‐Tellez, Manuel, additional, Saltz, Joel, additional, Sayed, Shahin, additional, Scott, Ely, additional, Siziopikou, Kalliopi P, additional, Sotiriou, Christos, additional, Stenzinger, Albrecht, additional, Sughayer, Maher A, additional, Sur, Daniel, additional, Fineberg, Susan, additional, Symmans, Fraser, additional, Tanaka, Sunao, additional, Taxter, Timothy, additional, Tejpar, Sabine, additional, Teuwen, Jonas, additional, Thompson, E Aubrey, additional, Tramm, Trine, additional, Tran, William T, additional, van der Laak, Jeroen, additional, van Diest, Paul J, additional, Verghese, Gregory E, additional, Viale, Giuseppe, additional, Vieth, Michael, additional, Wahab, Noorul, additional, Walter, Thomas, additional, Waumans, Yannick, additional, Wen, Hannah Y, additional, Yang, Wentao, additional, Yuan, Yinyin, additional, Zin, Reena Md, additional, Adams, Sylvia, additional, Bartlett, John, additional, Loibl, Sibylle, additional, Denkert, Carsten, additional, Savas, Peter, additional, Loi, Sherene, additional, Salgado, Roberto, additional, and Specht Stovgaard, Elisabeth, additional

Published
2023
Full Text
View/download PDF

28. HPV testing versus p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: results from the DAHANCA 19 study.

Author

Lilja-Fischer, Jacob Kinggaard, Kristensen, Morten Horsholt, Lassen, Pernille, Steiniche, Torben, Tramm, Trine, Stougaard, Magnus, Maare, Christian, Johansen, Jørgen, Primdahl, Hanne, Kristensen, Claus Andrup, Andersen, Maria, Eriksen, Jesper Grau, and Overgaard, Jens

Subjects
DNA analysis, RESEARCH, PAPILLOMAVIRUSES, CONFIDENCE intervals, IMMUNOHISTOCHEMISTRY, LOG-rank test, OROPHARYNGEAL cancer, EARLY detection of cancer, RANDOMIZED controlled trials, CANCER patients, PAPILLOMAVIRUS diseases, RESEARCH funding, DESCRIPTIVE statistics, DATA analysis software, SQUAMOUS cell carcinoma, LONGITUDINAL method
Abstract

The prognosis after primary (chemo-)radiotherapy for oropharyngeal squamous cell carcinoma (OPSCC) is affected by Human Papillomavirus (HPV) status, with a better prognosis in HPV-positive OPSCC. HPV-status is routinely assessed by p16 immunohistochemistry (IHC), but additional HPV DNA testing is debated. Also, there are numerous HPV genotypes, which prognostic role may need clarification. The purpose of this study was: (1) to test a custom-made targeted HPV next generation sequencing (NGS) panel in OPSCC, (2) to determine correlation with p16 IHC, and (3) to assess the impact of HPV DNA testing on outcome in the prospectively randomized clinical trial DAHANCA 19. We included 271 patients with OPSCC treated with primary (chemo-)radiotherapy in the DAHANCA 19 trial. Of these, 199 (73%) were p16-positive. HPV-status was determined by targeted HPV next generation sequencing (NGS), using a custom-made HPV genotyping panel. HPV was detected in 194 tumor samples. p16 IHC and NGS HPV status were concordant in 265 (98%) of 271 patients, whereas we did not detect HPV DNA in 5 p16-positive tumors. HPV16 accounted for 169 of 194 HPV-positive cases (87%). HPV genotypes 18, 31, 33, 35, and 59 were also detected. Loco-regional failure and overall survival were similar whether patients were separated by p16 IHC, or HPV DNA status (p < 0.0001 for all) and did not depend on HPV genotype (p = 0.9 and p = 0.7). In the present study, HPV DNA testing or typing in a Danish OPSCC cohort did not add additional information to p16 IHC, the most widely used and accepted prognostic indicator. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Supplementary Tables 1-5 from Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort

Author

Tramm, Trine, primary, Mohammed, Hayat, primary, Myhre, Simen, primary, Kyndi, Marianne, primary, Alsner, Jan, primary, Børresen-Dale, Anne-Lise, primary, Sørlie, Therese, primary, Frigessi, Arnoldo, primary, and Overgaard, Jens, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Document 1 from Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort

Author

Tramm, Trine, primary, Mohammed, Hayat, primary, Myhre, Simen, primary, Kyndi, Marianne, primary, Alsner, Jan, primary, Børresen-Dale, Anne-Lise, primary, Sørlie, Therese, primary, Frigessi, Arnoldo, primary, and Overgaard, Jens, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 1 from Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort

Author

Tramm, Trine, primary, Mohammed, Hayat, primary, Myhre, Simen, primary, Kyndi, Marianne, primary, Alsner, Jan, primary, Børresen-Dale, Anne-Lise, primary, Sørlie, Therese, primary, Frigessi, Arnoldo, primary, and Overgaard, Jens, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Document 2 from Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort

Author

Tramm, Trine, primary, Mohammed, Hayat, primary, Myhre, Simen, primary, Kyndi, Marianne, primary, Alsner, Jan, primary, Børresen-Dale, Anne-Lise, primary, Sørlie, Therese, primary, Frigessi, Arnoldo, primary, and Overgaard, Jens, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 3 from Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort

Author

Tramm, Trine, primary, Mohammed, Hayat, primary, Myhre, Simen, primary, Kyndi, Marianne, primary, Alsner, Jan, primary, Børresen-Dale, Anne-Lise, primary, Sørlie, Therese, primary, Frigessi, Arnoldo, primary, and Overgaard, Jens, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 2 from Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort

Author

Tramm, Trine, primary, Mohammed, Hayat, primary, Myhre, Simen, primary, Kyndi, Marianne, primary, Alsner, Jan, primary, Børresen-Dale, Anne-Lise, primary, Sørlie, Therese, primary, Frigessi, Arnoldo, primary, and Overgaard, Jens, primary

Published
2023
Full Text
View/download PDF

47. Amplified Ca2+ dynamics and accelerated cell proliferation in breast cancer tissue during purinergic stimulation

Author

Henningsen, Mikkel B., primary, McWhan, Kezia, additional, Dam, Vibeke S., additional, Mele, Marco, additional, Hauerslev, Katrine R., additional, Voss, Ninna C. S., additional, Dabir, Parag D., additional, Balling, Eva, additional, Pedersen, Helene L., additional, Vahl, Pernille, additional, Johansen, Tonje, additional, Tramm, Trine, additional, Christiansen, Peer M., additional, and Boedtkjer, Ebbe, additional

Published
2022
Full Text
View/download PDF

49. Validation of an Algorithm to Ascertain Late Breast Cancer Recurrence Using Danish Medical Registries

Author

Pedersen, Rikke Nørgaard, Öztürk, Buket, Mellemkjær, Lene, Friis, Søren, Tramm, Trine, Nørgaard, Mette, and Cronin-Fenton, Deirdre P

Subjects
Algorithm, Sensitivity, algorithm, Clinical Epidemiology, PPV, breast cancer neoplasm, sensitivity, Breast cancer neoplasm, Late breast cancer recurrence, late breast cancer recurrence, Original Research
Abstract

Rikke Nørgaard Pedersen,1 Buket Öztürk,1 Lene Mellemkjær,2 Søren Friis,2 Trine Tramm,3 Mette Nørgaard,1 Deirdre P Cronin-Fenton1 1Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark; 2Danish Cancer Society Research Center, Copenhagen, Denmark; 3Department of Pathology, Aarhus University Hospital, Aarhus, DenmarkCorrespondence: Rikke Nørgaard PedersenDepartment of Clinical Epidemiology, Aarhus University, Aarhus, DenmarkTel +4587167212Email rikp@clin.au.dkPurpose: About 70% of women with breast cancer survive at least 10 years after diagnosis. We constructed an algorithm to ascertain late breast cancer recurrence—which we define as breast cancer that recurs 10 years or more after primary diagnosis (excluding contralateral breast cancers)—using Danish nationwide medical registries. We used clinical information recorded in medical records as a reference standard.Methods: Using the Danish Breast Cancer Group clinical database, we ascertained data on 21,134 women who survived recurrence-free 10 years or more after incident stage I–III breast cancer diagnosed in 1987– 2004. We used a combination of Danish registries to construct the algorithm—the Danish National Patient Registry for information on diagnostic, therapeutic and procedural codes; and cancer diagnoses from the Danish Pathology Registry, the Danish Cancer Registry and the Contralateral Breast Cancer database. To estimate the positive predictive value (PPV), we selected 105 patients who, according to our algorithm, had late recurrence diagnosed at Aarhus University Hospital. To estimate the sensitivity, specificity and negative predictive value (NPV), we selected 114 patients diagnosed with primary breast cancer at Aalborg University Hospital. We abstracted clinical information on late recurrence for patients with medical record-confirmed late recurrence at Aarhus University Hospital.Results: Our algorithm had a PPV of late recurrence of 85.7% (95% CI: 77.5– 91.3%), a sensitivity of 100.0% (95% CI, 39.8– 100.0%), a specificity of 97.3 (95% CI, 92.2– 99.4) and a NPV of 100% (95% CI, 96.6– 100.0%).Conclusion: Our algorithm for late recurrence showed a moderate to high PPV and high sensitivity, specificity and negative predictive value. The algorithm could be an important tool for future studies of late breast cancer recurrence.Keywords: algorithm, late breast cancer recurrence, breast cancer neoplasm, PPV, sensitivity

Published
2020

50. Aquaporin‐5 in breast cancer

Author

Bystrup, Malte, primary, Login, Frédéric H., additional, Edamana, Sarannya, additional, Borgquist, Signe, additional, Tramm, Trine, additional, Kwon, Tae‐Hwan, additional, and Nejsum, Lene N., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results